Skip to Content

Canopy Growth Corp CGC

Morningstar Rating
$6.45 −0.22 (3.30%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

US Deals Help Unlock Some Value but Doesn't Help Canopy Growth's Lagging Canadian Operations

Canopy Growth grows and sells cannabis products primarily in Canada, which accounts for roughly 50% of sales. Unfortunately, the Canadian market is overloaded with too many licensed producers, leading to tough price competition and a stubbornly robust illicit market, so Canopy has yet to reach profitability. We forecast mid-single-digit growth over the next decade for the Canadian market, driven by the conversion of illicit consumers into the legal market. We expect competition to ease as continued industry losses drive consolidation.

Price vs Fair Value

CGC is trading at a 211% premium.
Price
$6.45
Fair Value
$1.80
Uncertainty
Extreme
1-Star Price
$57.40
5-Star Price
$9.68
Economic Moat
Nmhd
Capital Allocation
Rdtgj

Bulls Say, Bears Say

Bulls

Canopy Growth’s plans to create Canopy USA to strengthen its competitive position before US federal legalization.

Bears

While Canopy waits for US federal legalization to enter the THC market there, US multistate operators continue to grow bigger and become more competitive.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CGC is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$6.67
Day Range
$6.326.67
52-Week Range
$2.7619.20
Bid/Ask
$6.40 / $6.50
Market Cap
$491.47 Mil
Volume/Avg
2.6 Mil / 13.3 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
2.19
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare products under Martha Stewart CBD and Storz & Bickel vaporizers. Canopy growth merged its US assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
1,029

Competitors

Valuation

Metric
CGC
CRON
TLRY
Price/Earnings (Normalized)
1,432.96
Price/Book Value
1.590.830.38
Price/Sales
2.199.551.59
Price/Cash Flow
Price/Earnings
CGC
CRON
TLRY

Financial Strength

Metric
CGC
CRON
TLRY
Quick Ratio
1.0926.510.96
Current Ratio
1.5828.191.92
Interest Coverage
−3.63−4.39
Quick Ratio
CGC
CRON
TLRY

Profitability

Metric
CGC
CRON
TLRY
Return on Assets (Normalized)
−17.78%−0.28%−1.42%
Return on Equity (Normalized)
−46.87%−0.29%−1.82%
Return on Invested Capital (Normalized)
−16.41%−4.97%−0.92%
Return on Assets
CGC
CRON
TLRY
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
QhsgscrynQdk$79.1 Bil
Merck KGaA ADR
MKKGY
SchlmlzysWryxz$72.0 Bil
Haleon PLC ADR
HLN
ZryxtlvxNbl$37.3 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
GpsycvggkNyxqc$12.8 Bil
Viatris Inc
VTRS
XtpfspfvtLpkz$12.7 Bil
Catalent Inc
CTLT
BncgkxpbWrzdj$10.2 Bil
Perrigo Co PLC
PRGO
NbtnsjggHld$3.5 Bil
Prestige Consumer Healthcare Inc
PBH
SzhrdhbxRjrjlld$3.4 Bil
Green Thumb Industries Inc
GTBIF
MxbdzvwpQgtx$2.9 Bil
Curaleaf Holdings Inc
CURLF
SxlxfpnwQdym$2.8 Bil

Sponsor Center